All News about Neonmind Biosciences Inc
![](https://cdn.benzinga.com/files/images/story/2022/08/30/10_psychedelics_ceos_2_shutterstock_1.jpg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2022/04/25/psyched_cover_ver_2.jpg?width=1200&height=800&fit=crop)
Via Benzinga
![](https://cdn.benzinga.com/files/images/story/2022/04/22/mathew-schwartz-fk2e0nt2pgw-unsplash.jpg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2022/04/13/total-shape-ianw4rdvuoo-unsplash.jpg?width=1200&height=800&fit=crop)
Via Benzinga
![](/logos/subaccounts/thumbs/26972.jpg)
![](https://cdn.benzinga.com/files/images/story/2012/psyched_cover_ver_2_20.jpg?width=1200&height=800&fit=crop)
![](https://cdn2.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/marco-allegretti-3jsf1aft3mu-unsplash_3.jpg?width=720)
![](https://cdn2.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/psyched_cover_ver_2_18.jpg?width=720)
![](https://cdn2.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/marco-allegretti-3jsf1aft3mu-unsplash_0.jpg?width=720)
![](https://cdn2.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/neonmind.jpg?width=720)
![](https://cdn2.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/david-gabric-kdc5agsz6ik-unsplash46.jpg?width=720)
![](https://cdn2.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/nm-pr-website-headerdrbhayana.jpg?width=720)
![](https://cdn2.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/nick-fewings-0xppejp9lle-unsplash_0.jpg?width=720)
![](https://cdn.benzinga.com/files/images/story/2012/1_8_2.png?width=1200&height=800&fit=crop)
![](/logos/subaccounts/thumbs/26972.jpg)
![](/logos/subaccounts/thumbs/26972.jpg)
![](/logos/subaccounts/thumbs/26972.jpg)
![](/logos/subaccounts/thumbs/26972.jpg)
![](/logos/subaccounts/thumbs/26972.jpg)
NeonMind Biosciences Named as a Top Industry Innovator in Inaugural Issue of Psychedelia Magazine
November 05, 2021
Via AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
![](/logos/subaccounts/thumbs/26972.jpg)
NeonMind Advances Strategy for Specialty Clinic Launch
September 28, 2021
Via AccessWire
Topics
Intellectual Property
![](https://cdn2.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/psyched_cover_ver_2_6.jpg?width=720)
![](/logos/subaccounts/thumbs/26972.jpg)
![](https://cdn2.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/pexels-anna-nekrashevich-6801874_4.jpg?width=720)
![](/logos/subaccounts/thumbs/26972.jpg)
NeonMind Appoints Ketamine and Neurostimulation Expert Dr. Roumen Milev, MD, PhD to Specialty Clinic Advisory Board
September 16, 2021
Via AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
![](/logos/subaccounts/thumbs/26972.jpg)
NeonMind Announces Divestiture of Consumer Related and Other Non-Core Assets
September 13, 2021
Via AccessWire
Topics
Intellectual Property
![](/logos/subaccounts/thumbs/26972.jpg)
![](/logos/subaccounts/thumbs/26972.jpg)
NeonMind Announces DTC Eligibility
August 25, 2021
Via AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
![](/logos/subaccounts/thumbs/26972.jpg)
NeonMind Receives Health Canada Approval for its Functional Mushroom Formulation 'Mindful Blend'
August 17, 2021
Via AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.